$IDYA

Mizuho reduced its price target for Ideaya Biosciences (IDYA) to $39 from $44, citing dilution from Q2 2026 financing. The stock trades at $31.25 with a $3B market cap. Analysts maintain a Strong Buy consensus, with targets ranging from $30 to $66. Ideaya's pipeline includes darovasertib, pending FDA approval for metastatic uveal melanoma, and IDE849 for small cell lung cancer. Several analysts recently adjusted targets and ratings, reflecting expectations for commercial transformation in 2027.

Citigroup reaffirmed its Buy rating for IDEAYA Biosciences and increased its price target to $66 from $65. This target suggests a 115.3% upside from the Nov 5 closing price of $30.65. Recent analyst price targets for the company range from $45 to $63.

RBC Capital kept IDEAYA Biosciences at Outperform but reduced its price target to $45 from $48, a 6.2% cut. The new target suggests a 43.6% upside from the Nov 3 close of $31.33. Recent analyst notes on IDEAYA Biosciences have price targets ranging from $48 to $63.

Guggenheim kept IDEAYA Biosciences at Buy but reduced its price target to $52 from $57, citing an 8.8% decrease. The new target suggests a 66.0% upside from the Nov 3 close of $31.33. Recent analyst price targets for IDEAYA range from $48 to $63.

Wedbush kept its Outperform rating on IDEAYA Biosciences and increased its price target to $63 from $60, suggesting a 101.1% upside from the Nov 3 close of $31.33.

Truist Securities lowered its price target on Ideaya Biosciences (IDYA) to $57 from $59, maintaining a Buy rating. The adjustment follows Q3 results and a management meeting, citing potential commercial transformation in 2027. Ideaya discontinued a phase III study to focus on higher-priority programs, saving $100M-$125M. The company has a strong financial position with a current ratio of 10.45. Multiple analysts have recently rated IDYA positively, with price targets ranging from $31 to $65.

IDEAYA Biosciences reported Q3 2026 results, highlighting NDA submission for darovasertib in metastatic uveal melanoma and positive clinical data for darovasertib and IDE849 at ESMO 2026. The company has $1.15B in cash and expects runway into 2030. IDEAYA plans to initiate Phase 3 trials for IDE849 and provided updates on its MTAP pathway programs. (IDYA)

IDEAYA Biosciences (IDYA) reported updated Phase 1 results for IDE849, its DLL3-targeting ADC, at ESMO 2026. The study showed promising anti-tumor activity and preliminary overall survival in relapsed SCLC and NECs, with median OS of 17.4 months in 2L SCLC and 14.7 months in 2L + ≥3L SCLC. IDEAYA plans to initiate Phase 3 trials for ES-SCLC and NEC, targeting initiation following successful FDA meetings.

IDEAYA Biosciences and Servier presented clinical trial data at ESMO 2026, showing positive results for darovasertib in treating uveal melanoma. OptimUM-01 data showed 7.4-month PFS and 27.1-month mOS in treatment-naïve patients. OptimUM-02 data confirmed improvements in ORR and PFS across subgroups. OptimUM-09 data demonstrated 57% eye preservation rate and 66% radiation dose reduction in primary UM patients.

William Blair initiated coverage on Ideaya Biosciences (NASDAQ:IDYA) with an outperform rating, citing potential 2027 approval for darovasertib, its lead product for metastatic uveal melanoma. The company showed strong Phase III data, with a strong balance sheet and a buy consensus rating. Analysts highlight regulatory and clinical risks but see potential in earlier-stage treatments and other pipeline products.